219 related articles for article (PubMed ID: 37455404)
1. Safety of Diazepam Nasal Spray in Pediatric Patients With Developmental Epileptic Encephalopathies: Results From a Long-term Phase 3 Safety Study.
Tarquinio D; Wheless JW; Segal EB; Misra SN; Rabinowicz AL; Carrazana E
J Child Neurol; 2023 May; 38(6-7):389-393. PubMed ID: 37455404
[TBL] [Abstract][Full Text] [Related]
2. Concomitant cannabidiol does not impact safety and effectiveness of diazepam nasal spray for seizure clusters: Post hoc analysis of a phase 3 safety study.
Peters JM; Puri V; Segal E; Misra SN; Rabinowicz AL; Carrazana E
Epilepsy Behav; 2023 Jul; 144():109248. PubMed ID: 37210793
[TBL] [Abstract][Full Text] [Related]
3. Final results from a Phase 3, long-term, open-label, repeat-dose safety study of diazepam nasal spray for seizure clusters in patients with epilepsy.
Wheless JW; Miller I; Hogan RE; Dlugos D; Biton V; Cascino GD; Sperling MR; Liow K; Vazquez B; Segal EB; Tarquinio D; Mauney W; Desai J; Rabinowicz AL; Carrazana E;
Epilepsia; 2021 Oct; 62(10):2485-2495. PubMed ID: 34418086
[TBL] [Abstract][Full Text] [Related]
4. Safety of Diazepam Nasal Spray in Children and Adolescents With Epilepsy: Results From a Long-Term Phase 3 Safety Study.
Tarquinio D; Dlugos D; Wheless JW; Desai J; Carrazana E; Rabinowicz AL
Pediatr Neurol; 2022 Jul; 132():50-55. PubMed ID: 35636283
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of diazepam nasal spray in patients with epilepsy concomitantly using maintenance benzodiazepines: An interim subgroup analysis from a phase 3, long-term, open-label safety study.
Segal EB; Tarquinio D; Miller I; Wheless JW; Dlugos D; Biton V; Cascino GD; Desai J; Hogan RE; Liow K; Sperling MR; Vazquez B; Cook DF; Rabinowicz AL; Carrazana E;
Epilepsia; 2021 Jun; 62(6):1442-1450. PubMed ID: 33942315
[TBL] [Abstract][Full Text] [Related]
6. Use of second doses of Valtoco® (diazepam nasal spray) across 24 hours after the initial dose for out-of-hospital seizure clusters: Results from a phase 3, open-label, repeat-dose safety study.
Sperling MR; Wheless JW; Hogan RE; Dlugos D; Cascino GD; Liow K; Rabinowicz AL; Carrazana E;
Epilepsia; 2022 Apr; 63(4):836-843. PubMed ID: 35112342
[TBL] [Abstract][Full Text] [Related]
7. Quality-of-life results in adults with epilepsy using diazepam nasal spray for seizure clusters from a long-term, open-label safety study.
Cramer JA; Faught E; Davis C; Misra SN; Carrazana E; Rabinowicz AL
Epilepsy Behav; 2022 Sep; 134():108811. PubMed ID: 35816831
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and safety of VALTOCO (NRL-1; diazepam nasal spray) in patients with epilepsy during seizure (ictal/peri-ictal) and nonseizure (interictal) conditions: A phase 1, open-label study.
Hogan RE; Tarquinio D; Sperling MR; Klein P; Miller I; Segal EB; Rabinowicz AL; Carrazana E
Epilepsia; 2020 May; 61(5):935-943. PubMed ID: 32338380
[TBL] [Abstract][Full Text] [Related]
9. Consistent safety and tolerability of Valtoco
Miller I; Wheless JW; Hogan RE; Dlugos D; Biton V; Cascino GD; Sperling MR; Liow K; Vazquez B; Segal EB; Tarquinio D; Mauney W; Desai J; Rabinowicz AL; Carrazana E;
Epilepsia Open; 2021 Sep; 6(3):504-512. PubMed ID: 34033266
[TBL] [Abstract][Full Text] [Related]
10. Significant improvements in SEIzure interVAL (time between seizure clusters) across time in patients treated with diazepam nasal spray as intermittent rescue therapy for seizure clusters.
Misra SN; Sperling MR; Rao VR; Peters JM; Davis C; Carrazana E; Rabinowicz AL
Epilepsia; 2022 Oct; 63(10):2684-2693. PubMed ID: 35975599
[TBL] [Abstract][Full Text] [Related]
11. Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome.
Lattanzi S; Trinka E; Striano P; Rocchi C; Salvemini S; Silvestrini M; Brigo F
CNS Drugs; 2021 Mar; 35(3):265-281. PubMed ID: 33754312
[TBL] [Abstract][Full Text] [Related]
12. A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox-Gastaut syndrome (ELEKTRA).
Hahn CD; Jiang Y; Villanueva V; Zolnowska M; Arkilo D; Hsiao S; Asgharnejad M; Dlugos D
Epilepsia; 2022 Oct; 63(10):2671-2683. PubMed ID: 35841234
[TBL] [Abstract][Full Text] [Related]
13. Lack of observed tolerance to diazepam nasal spray (Valtoco®) after long-term rescue therapy in patients with epilepsy: Interim results from a phase 3, open-label, repeat-dose safety study.
Cascino GD; Tarquinio D; Wheless JW; Hogan RE; Sperling MR; Liow K; Desai J; Davis C; Rabinowicz AL; Carrazana E;
Epilepsy Behav; 2021 Jul; 120():107983. PubMed ID: 33957437
[TBL] [Abstract][Full Text] [Related]
14. Analysis of seizure-cluster circadian periodicity from a long-term, open-label safety study of diazepam nasal spray.
Fountain NB; Quigg M; Murchison CF; Carrazana E; Rabinowicz AL
Epilepsia; 2024 Apr; 65(4):920-928. PubMed ID: 38391291
[TBL] [Abstract][Full Text] [Related]
15. Rapid Rescue Treatment with Diazepam Nasal Spray Leads to Faster Seizure Cluster Termination in Epilepsy: An Exploratory Post Hoc Cohort Analysis.
Misra SN; Jarrar R; Stern JM; Becker DA; Carrazana E; Rabinowicz AL
Neurol Ther; 2024 Feb; 13(1):221-231. PubMed ID: 38175488
[TBL] [Abstract][Full Text] [Related]
16. Predictors of genetic diagnosis in individuals with developmental and epileptic encephalopathies.
Luiza Benevides M; de Moraes HT; Granados DMM; Bonadia LC; Sauma L; Augusta Montenegro M; Guerreiro MM; Lopes-Cendes Í; Carolina Coan A
Epilepsy Behav; 2024 Jun; 155():109762. PubMed ID: 38636144
[TBL] [Abstract][Full Text] [Related]
17. A phase 1b/2a study of soticlestat as adjunctive therapy in participants with developmental and/or epileptic encephalopathies.
Halford JJ; Sperling MR; Arkilo D; Asgharnejad M; Zinger C; Xu R; During M; French JA
Epilepsy Res; 2021 Aug; 174():106646. PubMed ID: 33940389
[TBL] [Abstract][Full Text] [Related]
18. Lack of clinically relevant differences in safety and pharmacokinetics after second-dose administration of intranasal diazepam within 4 h for acute treatment of seizure clusters: A population analysis.
Cascino GD; Tarquinio D; Wheless JW; Hogan RE; Sperling MR; Desai J; Vazquez B; Samara E; Misra SN; Carrazana E; Rabinowicz AL;
Epilepsia; 2022 Jul; 63(7):1714-1723. PubMed ID: 35377464
[TBL] [Abstract][Full Text] [Related]
19. Outcomes from a Spanish Expanded Access Program on cannabidiol treatment in pediatric and adult patients with epilepsy.
Villanueva V; García-Ron A; Smeyers P; Arias E; Soto V; García-Peñas JJ; González-Alguacil E; Sayas D; Serrano-Castro P; Garces M; Hampel K; Tomás M; Lara J; de Toledo M; Barceló I; Aledo-Serrano A; Gil-Nagel A; Iacampo L; Falip M; Saiz-Diaz RA; Gómez-Ibañez A; Sopelana D; Sanchez-Larsen A; López-González FJ
Epilepsy Behav; 2022 Dec; 137(Pt A):108958. PubMed ID: 36327646
[TBL] [Abstract][Full Text] [Related]
20. Perampanel as adjuvant treatment in epileptic encephalopathies: A multicenter study in routine clinical practice.
Alonso-Singer P; Aguilar-Amat Prior MJ; Oliva-Navarro J; Massot-Tarrús A; Giráldez BG; Bermejo P; DeToledo-Heras M; Aledo-Serrano Á; Martínez-Cayuelas E; Tirado-Requero P; Velázquez-Fragua R; López-Sobrino G; Ojeda J
Epilepsy Behav; 2022 Sep; 134():108836. PubMed ID: 35870432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
